A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer
Public ClinicalTrials.gov record NCT05328908. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Open-label Study of Relatlimab-nivolumab Fixed-dose Combination Versus Regorafenib or Trifluridine + Tipiracil (TAS-102) for Participants With Later-lines of Metastatic Colorectal Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate relatlimab in combination with nivolumab, administered as a fixed-dose combination (nivolumab-relatlimab FDC, also referred to as BMS-986213) for the treatment of non-microsatellite instability high (MSI-H)/deficient mismatch repair (dMMR) metastatic colorectal cancer (mCRC) participants who failed at least 1 but no more than 4 prior lines of therapy for metastatic disease.
Study identification
- NCT ID
- NCT05328908
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 769 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 28, 2022 (Actual)
- Primary completion
- Jul 14, 2025 (Actual)
- Completion
- Jul 14, 2025 (Actual)
- Last update posted
- Aug 26, 2026
2022 – 2025
United States locations
- U.S. sites
- 20
- U.S. states
- 19
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0044 | Springdale | Arkansas | 72762-5328 | — |
| Local Institution - 0012 | Los Angeles | California | 90089-0112 | — |
| Local Institution - 0117 | Norwich | Connecticut | 06360-2753 | — |
| Local Institution - 0025 | Miami | Florida | 33176 | — |
| Local Institution - 0031 | Atlanta | Georgia | 30342 | — |
| Local Institution - 0071 | Boise | Idaho | 83712-6267 | — |
| Local Institution - 0081 | Fort Wayne | Indiana | 46805 | — |
| Massachusetts General Hospital, | Boston | Massachusetts | 02214 | — |
| Local Institution - 0042 | Ann Arbor | Michigan | 48109-1382 | — |
| Local Institution - 0043 | East Brunswick | New Jersey | 08816-3340 | — |
| Local Institution - 0009 | Durham | North Carolina | 27710 | — |
| Local Institution - 0082 | Cincinnati | Ohio | 45220 | — |
| Local Institution - 0095 | Columbus | Ohio | 43210-1240 | — |
| Local Institution - 0147 | Philadelphia | Pennsylvania | 19111-2434 | — |
| Local Institution - 0008 | Charleston | South Carolina | 29414 | — |
| Local Institution - 0096 | Sioux Falls | South Dakota | 57104 | — |
| Local Institution - 0127 | Nashville | Tennessee | 37203-2173 | — |
| Local Institution - 0097 | Fort Worth | Texas | 76104-4611 | — |
| Local Institution - 0132 | Richmond | Virginia | 23284 | — |
| Local Institution - 0005 | Madison | Wisconsin | 53705-2275 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 119 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05328908, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 26, 2026 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05328908 live on ClinicalTrials.gov.